Navigation Links
Endologix Announces Pricing of Public Offering of Common Stock

IRVINE, Calif., July 30 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX) today announced that it has entered into an agreement to sell 3,900,000 shares of its common stock in an underwritten public offering at a price to the public of $4.10 per share. The gross proceeds to Endologix, before offering expenses, from the sale of shares are expected to be $15,990,000. The closing of the offering is expected to take place on August 4, 2009. Piper Jaffray & Co. will be the sole manager for the offering.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on May 8, 2009 that became effective on June 1, 2009. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. When available, copies of the prospectus supplement relating to the offering may be obtained upon request to Piper Jaffray & Co., at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at

Forward-Looking Statements

This press release contains forward-looking statements regarding the proposed offering by Endologix. Endologix intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. These statements are based on the current assumptions of the Company's management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause actual results to differ materially from those indicated by forward-looking statements. Factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in greater detail under the heading "Risk Factors" contained in the Company's periodic SEC filings. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. The Company undertakes no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

    Endologix, Inc.
    John McDermott, CEO
    (949) 595-7200

    The Ruth Group
    Nick Laudico (646) 536-7030
    Zack Kubow (646) 536-7020

SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Endologix Reports 42% Second Quarter 2009 Revenue Growth
2. Endologix to Report Second Quarter 2009 Financial Results on July 22, 2009
3. Endologix Added to Russell Indexes
4. Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17, 2009 at 4:15 p.m. ET
5. Endologix Receives Nasdaq Letter on Director Independence
6. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
7. BD Announces Results for Third Fiscal Quarter
8. Prepaid Emergency Travel Announces a Unique Service That Provides Peace of Mind During Family Emergencies
9. The Mills Group LLC Announces ElderCare/PrimePlus Service
10. Tampa Bay Radiation Oncology Announces New Full Service Center at Bruce B Downs
11. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2009 Earnings Release Date and Teleconference
Post Your Comments:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: